-
公开(公告)号：KR1020040059139A
公开(公告)日：2004-07-05
申请号：KR1020020085716
申请日：2002-12-28
Applicant: (주)아모레퍼시픽
IPC: A61K31/704
CPC classification number: A61K31/70
Abstract: PURPOSE: Provided is a controlling agent of Bcl-2 expression which characteristically contains ginsenoside F1(20-O-beta-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the formula(1), as an active ingredient. It prevents apoptosis caused by radiating low doses of ultraviolet rays, while promoting apoptosis when radiating high doses of ultraviolet rays, therefore it removes the risk of cancers. CONSTITUTION: A controlling agent of the expression of Bcl-2 is characterized by containing ginsenoside F1(20-O-beta-D-glucopyranosyl-20(S)-protopanaxatriol), which is represented by the formula(1), as an active ingredient. It inhibits the decrease of Bcl-2 expression caused by radiating ultraviolet rays. Therefore, it prevents apoptosis by the radiation of low doses of ultraviolet rays, but promotes apoptosis by the radiation of high doses of ultraviolet rays.
Abstract translation: 目的：提供一种Bcl-2表达的控制剂，其特征在于含有式（1）所示的人参皂甙F1（20-O-β-D-吡喃葡萄糖基-20（S） - 原人参三醇）作为活性成分。 防止辐射低剂量紫外线引起的细胞凋亡，同时在辐射高剂量的紫外线时促进细胞凋亡，从而消除癌症的风险。 构成：Bcl-2表达的控制剂的特征在于将由式（1）表示的人参皂甙F1（20-O-β-D-吡喃葡萄糖基-20（S） - 原人参三醇）作为活性物质 成分。 它抑制由辐射紫外线引起的Bcl-2表达的降低。 因此，通过低剂量的紫外线辐射可防止细胞凋亡，但通过高剂量紫外线的辐射促进细胞凋亡。
-
公开(公告)号：KR101729137B1
公开(公告)日：2017-04-26
申请号：KR1020090068784
申请日：2009-07-28
Applicant: (주)아모레퍼시픽
IPC: A61K31/722 , A61P3/02 , A23L1/30
CPC classification number: A61K31/722 , A23L33/28 , A23V2002/00 , A23V2250/511 , A23V2200/33
Abstract: 키토올리고당을유효성분으로함유하는항피로조성물이개시된다. 상기조성물은피로회복효과를나타내며, 이를통해건강식품또는의약분야에서다양하게활용가능하다.
Abstract translation: 公开了含有壳寡糖作为活性成分的抗疲劳组合物。 该组合物具有疲劳恢复效果，因此可用于保健食品或医药领域的各种领域。
-
公开(公告)号：KR101481041B1
公开(公告)日：2015-01-12
申请号：KR1020070123840
申请日：2007-11-30
Applicant: (주)아모레퍼시픽
IPC: A61K31/105 , A61K31/145 , A61P3/04
Abstract: 본 발명은 하기 화학식 1의 화합물을 활성성분으로 함유하는 지방세포 분화 억제용 조성물에 관한 것으로, 상기 화합물은 생체 내에서 지방 합성에 중요한 역할을 하는 글루코오스-6-인산 탈수소효소(glucose-6-phosphate dehydrogenase)의 활성을 억제함으로써 지방 합성 및 지방세포의 분화를 억제시키므로, 비만, 고지혈증 등의 지방대사 이상질환에 대한 예방 또는 치료용 조성물로 유용하게 사용될 수 있다:
화학식 1
상기 식에서,
X는 O 또는 S이고;
Y는 또는 이고;
R
1 은 H 또는 C
1-6 알킬이고;
R
2 및 R
3 는 각각 독립적으로 H 또는 OH이다.-
公开(公告)号：KR101349185B1
公开(公告)日：2014-01-16
申请号：KR1020060121960
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/166 , A61K31/045 , A61P3/04
Abstract: 본 발명은 지방대사 이상질환의 치료 및 예방용 약학 조성물에 관한 것으로, 화학식 1의 화합물을 유효성분으로 포함하는 본 발명의 약학 조성물은 인간 간세포에서 생체내 에너지 대사에 중요한 역할을 하는 아이소싸이트레이트 탈수소효소 3α (IDH3α) 프로모터와 카르니틴 팔미토일 트랜스퍼레이즈 1A (CPT1A) 프로모터의 활성을 증가시켜, 혈당 및 중성지방의 감소 및 결과적으로 체중의 감소를 가져오므로, 비만, 고지혈증, 당뇨병 등의 지방대사 이상질환의 예방 및 치료에 유용하게 사용될 수 있다.
-
35.发明公开2,5-비스-아릴-3,4-디메틸테트라하이드로퓨란 리그난을 유효성분으로 포함하는 에이엠피케이의 활성화에 의해 매개되는 비만 관련 질환의 예방 또는 치료용 조성물 有权2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS作为AMPK激活剂，以及用于预防和治疗代谢综合征的组合物，通过激活其中含有活性成分的AMPK酶
公开(公告)号：KR1020100129481A
公开(公告)日：2010-12-09
申请号：KR1020090048065
申请日：2009-06-01
Applicant: 조선대학교산학협력단 , (주)아모레퍼시픽
IPC: A61K36/185 , A61P3/04 , A23L1/30 , A61K31/341
CPC classification number: A61K36/185 , A61K31/341 , A61K2236/333
Abstract: PURPOSE: A Myristica fragrans-derived 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan is provided to activates AMP-activated protein kinase(AMPK) and to prevent and treat metabolic syndrome-associated diseases. CONSTITUTION: A Myristica fragrans extract is obtained by isolating Myristica fragrans with 10-30% of ethanol solution and contains lignin compounds of nectandrin B, nectandrin A, fragransin C1, verrucosin, saucernetin or tetrahydrofuroguaiacin. A functional food for treating obesity or metabolic syndrome contains Myristica fragrans extract.
Abstract translation: 目的：提供肉豆蔻衍生的2,5-双 - 芳基-3,4-二甲基四氢呋喃木脂素以激活AMP-活化的蛋白激酶（AMPK）并预防和治疗代谢综合征相关疾病。 构成：通过用10-30％的乙醇溶液分离肉豆蔻，获得肉豆蔻提取物，并含有nectandrin B，nectandrin A，fragransin C1，verrucosin，saucernetin或四氢呋喃桂皮素的木质素化合物。 用于治疗肥胖症或代谢综合症的功能性食物包含肉豆蔻提取物。
-
Patent Agency Ranking36.发明公开ＰＧＣ1-알파 프로모터를 발현하는 형질감염 세포주 및이를 이용한 ＰＧＣ1-알파 프로모터 부위의 활성을측정하는 방법 无效表达PGC1-ALPHA促进剂的转染细胞系和测量PGC1-ALPHA促进剂位点的活性的方法
公开(公告)号：KR1020090057834A
公开(公告)日：2009-06-08
申请号：KR1020070124591
申请日：2007-12-03
Applicant: (주)아모레퍼시픽
Abstract: A method for measuring the activity of transfection cell line and PGC1-alpha promoter is provided to search a material inducing the expression of PGC1-alpha and easily measuring the activity of PGC1-alpha promoter site. A transfection cell line which expresses a PGC1-alpha is transfected by a vector containing human PGC1-alpha promoter, antibiotic resistance gene, and reporter gene. The antibiotic resistance gene has neomycin and kanamycin. The reporter gene is luciferase gene. The vector is plasmid. A method for measuring the activity of PGC1-alpha promoter site comprises: a step of treating a PGC1-alpha promoter regulation material in the transfected cell line; and a step of measuring the activity of reporter gene.
Abstract translation: 提供了一种测量转染细胞系和PGC1-α启动子的活性的方法，以搜索诱导PGC1-α表达的物质，并容易测定PGC1-α启动子位点的活性。 通过含有人PGC1-α启动子，抗生素抗性基因和报道基因的载体转染表达PGC1-α的转染细胞系。 抗生素抗性基因具有新霉素和卡那霉素。 报告基因为萤光素酶基因。 载体是质粒。 测量PGC1-α启动子位点活性的方法包括：处理转染细胞系中PGC1-α启动子调节物质的步骤; 以及测定报道基因的活性的步骤。
-
公开(公告)号：KR1020090056611A
公开(公告)日：2009-06-03
申请号：KR1020070123840
申请日：2007-11-30
Applicant: (주)아모레퍼시픽
IPC: A61K31/105 , A61K31/145 , A61P3/04
Abstract: A composition containing a compound which suppresses the activation of a glucose-6-phosphate dehydrogenase for inhibiting the adipocyte differentiation is provided to suppress the lipid synthesis and adipocyte differentiation and treat the disorder of lipid metabolism such as obesity and hyperlipidemia. An inhibitor of glucose-6-phosphate dehydrogenase activation is denoted by the chemical formula 1. In the chemical formula 1, X is O or S, R1 is H or C1-6 alkyl, R2 and R3 is individually H or OH. The compound of the chemical formula 1 is 1,3di-(E)-N'-(2,3-dihydroxybenzylidene)thiohydrazide of the chemical formula 1a or (E)-3-(3-ethoxyphenyl)-N'-(2-hydroxy benzylidene)-1H-pyrazole-5-carbohydrazide of the chemical formula 1b. The composition is used in a form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosole, soft or hard gelatin capsule, or sterilization powder.
Abstract translation: 提供含有抑制葡萄糖-6-磷酸脱氢酶活化以抑制脂肪细胞分化的化合物的组合物，以抑制脂质合成和脂肪细胞分化，并治疗诸如肥胖症和高脂血症的脂质代谢紊乱。 葡萄糖-6-磷酸脱氢酶活化的抑制剂由化学式1表示。在化学式1中，X为O或S，R 1为H或C 1-6烷基，R 2和R 3为H或OH。 化学式1的化合物是化学式为1a的1,3-二（E）-N' - （2,3-二羟基亚苄基）硫代酰肼或（E）-3-（3-乙氧基苯基）-N' - （2 - 羟基亚苄基）-1H-吡唑-5-碳酰肼。 组合物以片剂，丸剂，粉末，香囊，酏剂，悬浮液，乳液，溶液，糖浆，气溶胶，软或硬明胶胶囊的形式或灭菌粉末的形式使用。
-
公开(公告)号：KR1020080051239A
公开(公告)日：2008-06-11
申请号：KR1020060121960
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/166 , A61K31/045 , A61P3/04
Abstract: A pharmaceutical composition comprising compounds capable of increasing expressions of isocitrate dehydrogenase 3alpha(IDH3alpha) and carnitine palmitoyl transferase 1A(CPT1A) by increasing activity of their promoters is provided to reduce synthesis of fatty acid and promote oxidation of fatty acid, so that the composition is useful for treating and preventing lipid metabolism-related diseases. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1) in which R1 is adamantly group or phenyl group substituted by H, OH or C1-C5 alkyl, and R2 is CONH or NHCO, and further comprises pharmaceutically acceptable carriers, excipients or diluents selected from lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, crystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
Abstract translation: 提供了包含通过提高其启动子的活性而能够增加异柠檬酸脱氢酶3α（IDH3α）和肉碱棕榈酰转移酶1A（CPT1A）的表达的化合物的药物组合物，用于减少脂肪酸的合成并促进脂肪酸的氧化，使得组合物 用于治疗和预防脂质代谢相关疾病。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R1是金刚烷基或被H，OH或C1-C5烷基取代的苯基，R2是CONH或NHCO， 包括药学上可接受的载体，赋形剂或稀释剂，其选自乳糖，葡萄糖，蔗糖，山梨糖醇，甘露糖醇，木糖醇，赤藓糖醇，麦芽糖醇，淀粉，阿拉伯胶，藻酸盐，明胶，磷酸钙，硅酸钙，纤维素，甲基纤维素，结晶纤维素，聚乙烯吡咯烷酮 ，水，羟基苯甲酸甲酯，羟基苯甲酸丙酯，滑石，硬脂酸镁和矿物油。
-
公开(公告)号：KR1020080038870A
公开(公告)日：2008-05-07
申请号：KR1020060106362
申请日：2006-10-31
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/198 , A61K31/205 , A61K31/35 , A61K2300/00
Abstract: A composition comprising an extract of soybean including isoflavone, carnitine, caffeine and arginine is provided to promote fat decomposition and fat oxidation and recover insulin sensitivity by increasing expression of adiponectin and a Glut4 gene, thereby showing anti-obese and anti-diabetic effect. A composition for improving obesity and diabetes comprises 0.0001-10 wt.% of isoflavone and 0.001-40 wt.% of L-carnitine as effective ingredients. The composition further comprises 0.0001-10 wt.% of caffeine and 0.001-40 wt.% of arginine. The composition is a health functional food or a medicine and is formulated into tablet, capsule, soft capsule, pill, granule, drink, diet bar, chocolate, caramel or confectionary.
Abstract translation: 提供包含异黄酮，肉碱，咖啡因和精氨酸的大豆提取物的组合物，以通过增加脂联素和Glut4基因的表达来促进脂肪分解和脂肪氧化并恢复胰岛素敏感性，从而显示出抗肥胖和抗糖尿病作用。 用于改善肥胖症和糖尿病的组合物包含0.0001-10重量％的异黄酮和0.001-40重量％的左旋肉碱作为有效成分。 组合物还包含0.0001-10重量％的咖啡因和0.001-40重量％的精氨酸。 该组合物是健康功能食品或药物，并配制成片剂，胶囊，软胶囊，丸剂，颗粒剂，饮料，饮食酒吧，巧克力，焦糖或糖果。
-
公开(公告)号：KR1020080035378A
公开(公告)日：2008-04-23
申请号：KR1020060102010
申请日：2006-10-19
Applicant: (주)아모레퍼시픽 , 재단법인서울대학교산학협력재단
IPC: A61K31/047 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase is provided to inhibit production of NADPH(nicotinamide adenine dinucleotide phosphate) and fat biosynthesis, so that the composition is useful for prevention and treatment of fat metabolism disorders including obesity, hyperlipidemia and diabetes. A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase comprises the compounds represented by the formula(1) selected from epigallocatechin gallate, gallocatechin gallate, epicatechin gallate, catechin gallate, octyl gallate and lauryl gallate, wherein R^1 is H or OH, R^2 is a structural formula 1 or 2, R^3 is C3-C20 alkyl, X is a structural formula 3 or 4, and R^4 is H or a structural formula 5; and the compounds represented by the formula(1) is quercetin or myricetin.
Abstract translation: 提供用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物以抑制NADPH（烟酰胺腺嘌呤二核苷酸磷酸酯）的产生和脂肪生物合成，使得该组合物可用于预防和治疗脂肪代谢障碍，包括肥胖症，高脂血症和糖尿病 。 用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物包括选自表没食子儿茶素没食子酸酯，没食子儿茶素没食子酸酯，表儿茶素没食子酸酯，儿茶素没食子酸酯，没食子酸辛酯和没食子酸月桂酯的式（1）表示的化合物，其中R 1是H或 OH，R 2是结构式1或2，R 3是C 3 -C 20烷基，X是结构式3或4，R 4是H或结构式5; 由式（1）表示的化合物是槲皮素或杨梅素。
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.03 seconds)
